Vigeo Therapeutics, a US-based clinical-stage immuno-oncology company, announced on Thursday new data from its phase I/II expansion study assessing single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM).

VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumour microenvironment (TME).

In a phase I/II clinical study in solid tumours (NCT03364400), VT1021 demonstrated promising single-agent clinical activity against recurrent glioblastoma. Among 22 evaluable subjects with rGBM, 3 had a complete response (CR), 1 had a partial response (PR), and 6 had stable disease (SD) with an average study duration of over 120 days. One subject continues to receive VT1021 treatment and has been on study for almost 3 years with no remaining measurable lesion. Historically, rGBM patients have a response rate of less than 5% and a median progression free survival of 48 days.

Vigeo COO and co-founder, Dr Jing Watnick, said, 'Demonstrating that the expected MOA of VT1021 in reprogramming the TME may be associated with better clinical outcomes in rGBM subjects confirms the efforts of our clinical development program.'